Ebvallo
1 known investors
EBVALLO is an on-demand allogeneic T-cell immunotherapy approved to treat relapsed or refractory EBV-positive post-transplant lymphoproliferative disease (PTLD) in patients whose disease has failed rituximab with or without chemotherapy. The page is a product site for this therapy targeting transplant patients with limited treatment options.
BiotechDigital Health
Investors · 1
Frequently asked questions
- What does Ebvallo do?
- EBVALLO is an on-demand allogeneic T-cell immunotherapy approved to treat relapsed or refractory EBV-positive post-transplant lymphoproliferative disease (PTLD) in patients whose disease has failed rituximab with or without chemotherapy. The page is a product site for this therapy targeting transplant patients with limited treatment options.
- Who are Ebvallo's investors?
- Ebvallo's investors include HEALTHCARE ROYALTY PARTNERS.